مقاله انگلیسی رایگان در مورد درمان فارماکولوژیک افسردگی پرناتال – الزویر 2018

Perinatal depression, defined as depressive symptoms occurring either during pregnancy (antenatal depression [AND]) or postpartum (postpartum depression [PPD])1,2 is exceedingly common and has serious implications when not adequately identified and treated. It has been estimated that between 14% and 23% of women experience AND,3 and up to 22% of women develop PPD within the first 12 months after delivery.4 Yet, it has also been estimated that only 30% to 50% of women with AND or PPD are identified in clinical settings, and an even smaller number (14%–16%) receive any treatment for their symptoms.

CONSEQUENCES OF PERINATAL DEPRESSION

Untreated AND has been associated with increased risks for preeclampsia and preterm birth, as well as the development of numerous chronic health complications in the mother, including diabetes, hypertension, and cardiovascular disease.6–8 Furthermore, untreated AND is one of the greatest risk factors for the development of PPD.3,9,10 Untreated PPD has been associated with unplanned weaning or lactation failure, toxic stress of the newborn, impaired bonding and attachment, and can adversely affect the mental and emotional health of the child through schoolage.11–19 PPD is often a trigger for onset of a chronic major depressive disorder, with almost 1 in 3 women continuing to struggle with depressive symptoms at least 4 years after delivery.20 Most important, PPD is considered to be the greatest risk factor for maternal suicide and infanticide.